Repros Therapeutics Inc. (RPRX) Social Stream



Repros Therapeutics Inc. (RPRX): $43.15

0.41 (+0.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RPRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Royalty Pharma plc (RPRX) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering RPRX.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-10 8 $56.001 $46 $51.714 $38.37 34.78%
2022-02-02 7 $56 $46 $51.714 $38.37 34.78%
2022-03-08 7 $56 $46 $51.142 $38.37 33.29%

The Trend in the Analyst Price Target


RPRX's average price target has moved down $1 over the prior 13 months.

Over the past 48 weeks, RPRX's average upside potential has been 29.31%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-03 6 56 47 52.29 43.01 21.58%
2021-04-17 6 56 47 52.29 41.87 24.89%
2021-08-14 9 56 50 52.63 38.73 35.89%
2021-08-28 9 56 46 51.50 39.19 31.41%
2021-09-11 10 56 46 51.43 38.48 33.65%

RPRX Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.71 4 1 2 0 0 7

The Trend in the Broker Recommendations


RPRX's average broker recommendation rating improved by 0.69 over the prior 26 weeks.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for RPRX as an investment opportunity.

  • Royalty Pharma plc's variance in analysts' estimates is lower than 59.49% of stocks in the large market cap category.
  • In the context of Pharmaceutical Products stocks, Royalty Pharma plc's upside potential (average analyst target price relative to current price) is higher than 47.76% of them.
  • RPRX has a greater number of analysts covering the stock than 53.83% of stocks in the large market cap category.
  • Royalty Pharma plc's average analyst price target is greater than 80.77% of stocks in the large market cap category.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Royalty Pharma plc are REGN, RDY, and RARE.

Is RPRX a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5947 seconds.